Coronavirus Update: Sanofi and GSK ‘Happy To Lose’ COVID-19 Vaccine Race
Plus: European Therapeutics Accelerator Launched
Heads of vaccines development at partners GSK and Sanofi:“This is not a sprint, it’s a marathon.”
You may also be interested in...
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
Magnus Christensen takes over as Medivir's interim CEO, while Yilmaz Mahshid joins the board. Meanwhile, bluebird bio appoints a new chief commercial officer for severe genetic disease and ARCA biopharma appoints a new CFO and VP of clinical development.